HPV rarely arrives alone. Co-infections with chlamydia, gonorrhoea and other STIs are common and almost always silent. Testing HPV and STIs on the same sample delivers a more complete diagnosis, with no new collection for the patient.
HPV testing has become one of the pillars of preventive care in women's health, and demand keeps growing. The virus is the main cause of cervical cancer, and the World Health Organization estimates that around 300 million women are currently living with the infection. For the laboratory, this means a constant flow of samples arriving every day with a clear question to answer.
The HPV result is reliable and guides important decisions. The point is a different one: the sample that reaches the laboratory carries far more information than a single test can show. Chlamydia, gonorrhoea, mycoplasmas and trichomoniasis may be there, in the same collection, waiting only for a broader request to appear on the report. When testing is limited to HPV, these infections stay off the radar, and the patient leaves with part of the answer when she could have the full picture.
This guide shows why HPV and other sexually transmitted infections should be investigated together, what a complete molecular panel adds to the report and how to bring this testing into your laboratory routine with no new collection, no new workflow and no complication.
Why look beyond HPV
A door that rarely opens on its own
Describing HPV as a gateway to other STIs is a direct way of expressing what epidemiology has observed for years. These infections share the same route of transmission and the same exposure factors, so finding one increases the chance of another. A study of 200 women seen at the gynaecology and obstetrics outpatient clinic of a university hospital in Rio Grande do Sul, Brazil, found HPV in 27.5% of them and Chlamydia trachomatis in 11%. Among HPV-positive patients, about one in eight also had chlamydia, and the authors concluded by recommending routine screening for the bacterium in these services.
The relationship also runs the other way. Bacterial and protozoal infections cause inflammation of the cervical epithelium, and this altered environment appears to favour viral persistence. A systematic review and meta-analysis published in 2022 in the Iranian Journal of Public Health, pooling studies with more than 5,000 participants, found a significant association between chlamydial infection and cervical cancer, with roughly twice the risk. The authors consider the role of HPV co-infection along this path biologically plausible, although the exact moment at which it acts depends on prospective studies. In clinical practice, the reading is simple: an STI that goes unnoticed may be part of the HPV story itself.
Silence is the rule, not the exception
The biggest challenge with STIs is that they rarely announce themselves. According to the WHO, more than 1 million curable sexually transmitted infections are acquired every day worldwide, and most cause no symptoms. In 2020 alone, an estimated 129 million new cases of chlamydia, 82 million of gonorrhoea and 156 million of trichomoniasis occurred among people aged 15 to 49.
Silent does not mean harmless. Chlamydia and gonorrhoea are among the leading causes of pelvic inflammatory disease and female infertility, as well as pregnancy complications. Mycoplasma genitalium follows the same path and is also accumulating antimicrobial resistance, which makes accurate diagnosis part of choosing the treatment. Trichomonas vaginalis, although common, is frequently underdiagnosed when testing relies only on wet-mount microscopy. A patient may leave the clinic with HPV screening up to date and one of these infections still active without anyone knowing.
What a complete panel delivers
Genotyping: HPV with a first and last name
Knowing that HPV is present is the first step. Knowing which HPV is present is what guides management. High oncogenic risk genotypes, notably 16 and 18, account for most cervical cancer cases, and patients carrying these types follow a different follow-up path from those with other genotypes. The Brazilian Guideline for Cervical Cancer Screening, published by the federal government in 2025, organises this management around the oncogenic HPV-DNA test result, which makes HPV genotyping information of direct use in the clinic, not a technical detail of the report.
Seven agents, one sample
Testing more does not require collecting more. Molecular biology allows the same sample used for HPV to be analysed by a real-time PCR panel capable of detecting, at once, the main STI agents of the genital tract: Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis, as well as Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum. The presence of these last three is interpreted in light of the clinical picture, since they may represent only colonisation in women without complaints.
The choice of method also matters. Some of these bacteria grow poorly or not at all in conventional culture, as is the case with Mycoplasma genitalium, and microscopy depends on the number of organisms present on the slide. PCR detection of genetic material overcomes these limitations, identifying the agent even at low load and without requiring it to reach the laboratory viable. For infections that tend to pass without symptoms, this sensitivity makes a difference precisely in cases where the test is the only clue available.
Together, HPV genotyping and the STI panel deliver in a single report a snapshot of the genital tract at the time of the visit, with no new collection for the patient and no extra return to the clinic.
The value of complete testing for your laboratory
More guidance for the physician, more weight for the report
For the requesting physician, the difference shows up in very concrete situations. A non-specific complaint, such as persistent discharge or mild pelvic pain, gains a defined cause. A co-infection is treated before it progresses to a complication. Treatment of the sexual partner is guided by the identified agent, reducing the risk of reinfection. And the patient leaves with a more complete answer about her own health from a single test.
Each of these answers reinforces the place of the report in clinical decision-making. A result that clarifies more questions is a result the physician reads more carefully, cites with more confidence to the patient and requests again more often.
Differentiation that starts with the request
In a market where HPV testing is already offered by many laboratories, the difference lies in what comes with it. Presenting STI testing as a natural extension of HPV positions the laboratory as a partner in care, not merely as the executor of a request. This strengthens the relationship with the clinical staff, increases the value of every collection that already happens and paves the way for complete testing to become, over time, the standard request in women's health.
Implementation without changing the routine
Same collection, same workflow
The main objection to expanding a panel is usually operational, and here it practically disappears. Cervicovaginal material collected in molecular transport medium for HPV also serves the STI panel, so the patient does not need a new collection, the professional does not need another kit and the laboratory does not need to reorganise the pre-analytical phase. Everything still depends on what has always been decisive in molecular biology: a sample that is well collected, well identified and well transported.
Together from the first request
The request originates in the clinic, and the message to clinical staff needs to be direct: the ideal moment to test for STIs is the same moment HPV is requested. When both tests are ordered together, the answer arrives complete in the first report. When the STI is left for later, it tends to be investigated only when it shows signs, and then the path is longer. The patient returns with persistent discharge or pelvic pain with no apparent cause, goes through a new consultation, a new collection and a new wait for a result that could have been ready from the start.
Ordering them together avoids this return, saves time where it matters, such as in prenatal follow-up, and reaches precisely those who most often escape diagnosis: women without symptoms, for whom the test is the only chance of the infection being found. When physicians see this gain in their own practice, ordering HPV and STIs together stops being the exception and becomes the standard.
How to choose a reference laboratory
Expanding diagnosis only makes sense with a partner able to sustain result quality in every sample. The first criterion is the team: multiplex panels require professionals specialised in molecular biology who conduct each analytical step rigorously and carefully interpret agents that may represent only colonisation. The second is technology, with up-to-date real-time PCR platforms, internal controls in every reaction and protocols that ensure traceability of every result. The third is turnaround time, since an STI result only fulfils its role if it arrives in time to guide treatment of the patient and partner.
Base Científica brings these three criteria together in women's health diagnostics: a team specialised in molecular biology, real-time PCR technology for HPV genotyping and the STI panel, and a single report, from the same sample, delivered within a timeframe that allows rapid action.
A report that answers more
The question is no longer whether it is worth testing for STIs together with HPV, but when this routine will enter your laboratory. Each HPV sample analysed in isolation is a diagnostic opportunity that rarely repeats itself: without symptoms, the patient seldom returns for a second collection, and it is in that interval that complications set in. Making the combined request the standard is the decision that places the laboratory at the centre of women's health care, with a report the physician recognises as complete from the first reading.
Shall we talk about your panel?
If your laboratory wants to offer HPV and STI testing in a single request, the Base Científica team is available to plan this path together with you.